Eligible patients
medulloblastoma, ependymoma, Cancer
PRIMARY BRAIN TUMORS, MEDULLOBLASTOMA, EPENDYMOMA, CANCER
Patients with recurrent medulloblastoma or ependymoma known to express B7H3 by immunohistochemical staining were eligible to receive cRIT with 131-I-omburtamab at Memorial Sloan Kettering Cancer Center (MSK) on an IRB-approved phase I protocol (NCT# 00089245) from 2004 TO 2019. Patients were eligible for the protocol if they had no rapidly deteriorating neurologic examination or obstructive hydrocephalus, an absolute neutrophil count > 1000/ul, platelet count > 50,000/ul, serum bilirubin < 3.0 mg/dl, and serum creatinine < 2 mg/dl. Ommaya catheter position, patency, and CSF flow were evaluated in all patients before treatment using 111-Indium diethylene triamine pentaacetic acid scintigraphy studies. There was no prior EBRT dose limit and at least a 3-week interval between most recent EBRT and cRIT. Patients and/or guardians provided informed consent for trial enrollment. For the purposes of evaluating patients with recurrent primary brain tumors, patients with recurrent ependymoma or medulloblastoma who received cRIT and at least one imaging response assessment were included.